Literature DB >> 17212227

Standardization of biological medicines: the first hundred years, 1900-2000.

Adrian F Bristow1, Trevor Barrowcliffe, Derek R Bangham.   

Abstract

The use of materials of biological origin in medicine has a long history. These materials, including tissue, organ and microbial extracts, blood and its derivatives, antibodies and hormones, share the feature that for much of the last century the ability to characterize and quantify the active substance was limited. Quantification of these substances depends on biological standardization, a discipline that was refined to a science by the Medical Research Council from the 1920s onwards, and which, with contributions from several prominent Fellows of the Royal Society, including principally Sir Henry Dale, the UK has led the world to the present date.

Mesh:

Substances:

Year:  2006        PMID: 17212227     DOI: 10.1098/rsnr.2006.0153

Source DB:  PubMed          Journal:  Notes Rec R Soc Lond        ISSN: 0035-9149            Impact factor:   0.826


  4 in total

Review 1.  Biologic agents in islet transplantation.

Authors:  Boris Gala-Lopez; Andrew R Pepper; A M James Shapiro
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

2.  'Wanted-standard guinea pigs': standardisation and the experimental animal market in Britain ca. 1919-1947.

Authors:  Robert G W Kirk
Journal:  Stud Hist Philos Biol Biomed Sci       Date:  2008-08-15

Review 3.  The Role of Reference Materials in the Research and Development of Diagnostic Tools and Treatments for Haemorrhagic Fever Viruses.

Authors:  Giada Mattiuzzo; Emma M Bentley; Mark Page
Journal:  Viruses       Date:  2019-08-24       Impact factor: 5.048

4.  International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab.

Authors:  Sandra Prior; Simon E Hufton; Bernard Fox; Thomas Dougall; Peter Rigsby; Adrian Bristow
Journal:  MAbs       Date:  2017-11-03       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.